{"schema_version":"secwatch.filing_event.v1","accession":"0002007919-26-000028","form_type":"8-K","ticker":"INBX","cik":"0002007919","company_name":"Inhibrx Biosciences, Inc.","filed_at":"2026-05-14T20:04:23+00:00","discovered_at":"2026-05-14T20:05:00.256001+00:00","generated_at":"2026-05-14T20:05:37.985971+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Inhibrx Q1 2026 net loss $33.4M; cash $161.7M; ozekibart BLA submitted","bullets":["Net loss $33.4M ($2.15/sh) vs $43.3M ($2.80/sh) YoY; R&D expense $25.2M down from $36.9M.","Cash $161.7M at Mar 31, 2026 vs $124.2M at Dec 31, 2025; $75M loan amendment from Oxford.","BLA submitted to FDA for ozekibart in conventional chondrosarcoma; discuss accelerated pathways for CRC and Ewing sarcoma.","INBRX-106 Phase 2 HNSCC updated interim data in May 2026; PFS results expected Q4 2026.","Debt increased to $175M; other expense $2.5M from higher interest on new $75M principal."],"urls":{"canonical":"https://secwatch.observer/filing/0002007919-26-000028","json":"https://secwatch.observer/filing/0002007919-26-000028.json","markdown":"https://secwatch.observer/filing/0002007919-26-000028.md","text":"https://secwatch.observer/filing/0002007919-26-000028.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2007919/000200791926000028/0002007919-26-000028-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2007919/000200791926000028/inhibrx-20260514.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T20:05:37.985971+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b4509dd6a62fad2a272f8a375651aa37525e81eb","claim":"Inhibrx Biosciences, Inc. reported the first quarter of 2026 results: net income $33.4 million, EPS $2.15 per share.","evidence_excerpt":"Net loss was $33.4 million during the first quarter of 2026, or $2.15 per share, basic and diluted","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/2007919/000200791926000028/0002007919-26-000028-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter of 2026"},{"label":"Net income","value":"$33.4 million"},{"label":"EPS","value":"$2.15 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}